My father developed diabetes after taking statin drugs. Never had an insulin problem before that. BUT, that's a different story. This research sounds promising and I hope it cures many.

~NightSky

~~~~~~~~

By Medical University of South Carolina
July 7, 2026

An engineered stem cell therapy reversed new-onset Type 1 diabetes in mice by shifting the immune system away from attacking insulin-producing cells.

For more than a century, people with Type 1 diabetes have relied on insulin to survive, but the treatment does not stop the immune system from continuing its attack on the body’s insulin-producing cells. Scientists have long searched for ways to address the underlying cause of the disease rather than simply managing its symptoms.

Now, researchers at the Medical University of South Carolina (MUSC) report an experimental stem cell therapy that reversed newly diagnosed Type 1 diabetes in a mouse model. The treatment, described in Molecular Therapy, was designed to reprogram the immune system and protect the insulin-producing cells that remain after disease onset, offering a potential new strategy for combating the autoimmune disorder.

“While insulin injections are lifesaving, they cannot stop immune attacks, and they do not prevent long-term complications,” said Wang. “This study suggests a new way to treat Type 1 diabetes by addressing the root cause – immune system dysfunction –rather than just managing blood sugar.”

The therapy is based on mesenchymal stem/stromal cells (MSCs), adult stem cells that can help repair tissue and regulate immune activity. Earlier clinical trials have suggested that standard MSCs may help preserve the insulin production that remains in people with T1D. The challenge is that the body’s intense inflammatory response can overpower those cells before they are able to reverse established disease.

To make the cells more resilient, the team engineered MSCs to produce alpha-1 antitrypsin (AAT), a protective protein that helps defend against inflammation. The modified AAT-MSCs appear to work in two ways at once, protecting surviving insulin-producing cells in the pancreas while also reducing the overactive immune attack. Co-senior author Charlie Strange, M.D., emphasized that this combined effect makes AAT-MSC treatment more potent than standard stem cell therapy.

After examining thousands of individual immune cells, they found that AAT-MSC infusion did more than quiet an overactive immune response. It appeared to reshape how the immune system behaved.

The therapy affects two opposing immune cell groups. T-regulatory cells act as peacekeepers, helping preserve insulin production in the pancreas, while CD8+ killer T-cells drive the attack that destroys insulin-producing cells. In T1D, the protective cells are present, but they are overwhelmed by a constant wave of attacking cells, which ultimately contributes to the loss of insulin production.

Another notable feature of the treatment was its durability. The stem cells disappeared from the body within hours or days, yet the immune system changes continued.

https://doi.org/10.1016/j.ymthe.2026.03.032